HCW Biologics (HCWB) Set to Announce Quarterly Earnings on Thursday

HCW Biologics (NASDAQ:HCWB) is expected to announce its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to post earnings of ($1.35) per share and revenue of $0.12 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

HCW Biologics (NASDAQ:HCWB) last issued its quarterly earnings data on Friday, August 14th. The company reported ($11.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). The firm had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.14 million. HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%.

HCW Biologics Trading Down 6.1%

HCWB stock opened at $1.08 on Thursday. The company has a market capitalization of $2.42 million, a P/E ratio of -0.04 and a beta of 2.31. HCW Biologics has a twelve month low of $1.08 and a twelve month high of $23.94. The business has a 50 day simple moving average of $1.85 and a 200-day simple moving average of $4.07.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, October 15th. Wall Street Zen upgraded shares of HCW Biologics from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, HCW Biologics has a consensus rating of “Hold” and a consensus target price of $30.00.

HCW Biologics Company Profile

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.